Dear Madam, dear Sir, dear Shareholder,

Welcome to our Investors section and thank you for your interest in our company.

Despite the continuing slowdown in activity in the French market due to a lack of staff in operating rooms, we recorded a solid year in 2022, marked by continued growth. This performance demonstrates the strength of the various partnerships that we were able to deploy abroad and confirms the strategic orientation that we were focused on over the last two years.

Following the success of our strategic repositioning in 2021, illustrated by the acquisition of OSD and the divestment of our Knee business to the MENIX Group, we focused on finalizing the globalization of our product offer dedicated to spine surgery. We also revitalized our presence in the United States, strengthening our existing team in Boston and preparing the launch of the Squale and Allures anterior cervical cages and plates from OSD’s product portfolio in the US market.

In addition to these significant advances, we signed a strategic partnership with Sanyou Medical, China’s second largest manufacturer of spinal implants. Our partner’s support was already evident in the capital increase we carried out at the end of October 2022, which it guaranteed up to €5 million. These funds will allow us to reinforce our R&D investments by relying on Sanyou Medical’s know-how, to secure our products at the regulatory level and to increase our commercial presence on our direct markets.

2023 will be marked by the implementation of our partnership with Sanyou Medical. This is a unique opportunity for us to strengthen our international presence by distributing the entire JAZZ® range in China, the world’s largest market in terms of volume. JAZZ® platform registration has begun in China. In France as well as for export, we hope to be able to record the first sales of the ultrasound surgical scalpel developed by Sanyou Medical subsidiary SMTP during the first quarter of 2023.

By building on all of these elements and capitalizing on our strategic partnerships, we have all the necessary levers at our disposal to develop our product offering and pursue our innovation policy in order to position Implanet as a major player in spine surgery. We are confident that we will be able to reach a new milestone and achieve financial stability in the medium term.

On behalf of the entire Implanet team, I would like to thank you for your trust.

Ludovic Lastennet Chief Executive Officer